



**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bengaluru 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

Date of submission: March 1, 2019

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

**Sub: Biocon Appoints Dr. Christiane Hamacher as CEO of Biocon Biologics India Limited.**

**Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.**

In compliance with the provisions of Regulation 30 of SEBI LODR Regulations 2015, please find enclosed herewith the subject press release being issued by the Company today.

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking you,  
Yours faithfully  
**For Biocon Limited**

Siddharth Mittal  
Chief Financial Officer

Press Release

## **Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited**

***Bengaluru, India: March 1, 2019:***

**Biocon Ltd** (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that Dr. Christiane Hamacher has been appointed as CEO of Biocon Biologics India Ltd. effective today.

Dr. Hamacher comes with more than 20 years of leadership experience in both strategic and operational roles across the value chain in global pharma, spanning Asia, Europe and the U.S. She has been with Roche, Basel, Switzerland since 2007 and prior to that spent 10 years at Schering AG, Berlin, Germany.

***Ms Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon, said: "I am delighted to welcome Christiane Hamacher as CEO of Biocon Biologics India Ltd. Christiane joins us at a critical inflexion point in the business as we build our stature in the large and growing opportunity for biosimilar biologics. I am confident that she will successfully lead the company to become a major global player in the near future. Being a woman leader, I believe she also brings a diversity perspective which is integral to our leadership journey."***

Dr. Hamacher is an accomplished international C-suite executive with a passion for setting the corporate vision, defining and implementing future-driven strategy and growing businesses through entrepreneurial innovation and patient-centricity. She has robust experience in steering complex, global matrix organizations, quickly building strong, trusting relationships to enable achievement of top-level results.

During her long career in the pharmaceutical industry, she has built expertise in the areas of oncology, virology, CNS, cardiovascular, gynaecology, diagnostics, dermatology, rheumatology and rare diseases.

She holds a Ph.D. in Molecular Biology (Oncology) from the University Clinic Bergmannsheil / University of Bochum, Germany. She also studied Economics at the University of Hagen, Germany.

Biocon Biologics India Ltd is a wholly-owned subsidiary of Biocon Ltd.



**About Biocon Ltd:**

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully-integrated, innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and taken differentiated Small Molecules, Novel Biologics and a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh- Insulin and Insulin Glargine) from 'Lab to Market' in India, key emerging and developed markets. It has a large portfolio of biosimilars under clinical development with three of these approved in developed markets of U.S., EU, Japan and Australia. Its Novel pipeline includes promising assets like Insulin Tregopil, anti-CD6 antibody and a fusion protein for immuno-oncology. Some of its key brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAB™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAB-EGFR® (Nimotuzumab) and ALZUMAB™ (Itolizumab). Follow-us on Twitter: @bioconlimited , [www.biocon.com](http://www.biocon.com)

*DISCLAIMER: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.*

<b>FOR MORE INFORMATION</b>	
<b>MEDIA RELATIONS</b> <b>Seema Ahuja</b> <b>VP &amp; Global Head, Corporate Communications</b> ☎ +91 80 2808 2222 📠 +91 99723 17792 ✉ <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a>	<b>INVESTOR RELATIONS</b> <b>Saurabh Paliwal</b> <b>Head, Investor Relations</b> ☎ +91 80 6775 2040 📠 +91 95383 80801 ✉ <a href="mailto:investor.relations@biocon.com">investor.relations@biocon.com</a>